Antitumor drugs future studies

Antitumor drugs cisplatin as, history, 37 175-179 platinum compounds future studies, 37 206-208 resistance to, 37 192-193 second-generation, 37 178 Antiviral agents, 36 37-38 AOR, see Aldehyde oxidoreductase Aphanothece sacrum, ferredoxins, amino acid sequence, 38 225-227 Apo-calcylin, 46 455 Apo-caldodulin, 46 449-450 Apoenzyme, 22 424 Apoferritin biosynthesis, 36 457 cystalline iron core, 36 423 Fe(III)distribution, 36 458-459 Fe(II) sequestration, 36 463-464 ferroxidase centers, 36 457-458 iron core reconstruction in shell, 36 457 mineralization, 36 25 Mdssbauer spectra, 36 459-460 optical absorbance spectra, 36 418-419 subunit conformation and quaternary structure, 36 470-471... 

The book concludes with Part 6 dealing with several new developments in the field of antitumor Pt compounds. Farrell et al. present novel di- and trinuclear Pt11 compounds which display marked antitumor activity and, at the same time, have DNA-binding properties different from those of cis-platin. Kelland describes orally active PtIV drugs presently in Phase-I and Phase-II clinical trials. New and fast mechanism-based methods for screening Pt compounds for potential antitumor activity are the topic of the chapter by Sandman and Lippard. Finally, Kozelka critically examines the contribution that computational studies can make to the field of Pt-nucleic acid interactions. He ends with an optimistic outlook for using ab initio molecular-dynamics calculations in the near future. 

The glutamate transporter-mediated increase of antitumor activity caused by theanine is a novel mechanism, and it is hoped that this action will lead to the discovery of a useful cancer chemotherapy for drug-sensitive, drug-resistant, and metastatic tumors. It was expected that this study will greatly contribute to clinical cancer chemotherapy in the future. ... 

Although maytansine has been studied in an extensive series of clinical trials, there does not appear to be sufficient antitumor activity and the future of maytansine as an anticancer drug appears doubtful (Reider and Roland, 1984). 

---